| Oct 8 |
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association
|
| Sep 19 |
Vivos Therapeutics announces $4.3M registered direct offering of common stock
|
| Sep 19 |
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
|
| Sep 19 |
Nvidia, T-Mobile US, Vivos Therapeutics, SoFi Technologies, Tesla: Why These 5 Stocks Are On Investors' Radars Today
|
| Sep 18 |
Vivos surges on FDA nod for pediatric sleep apnea device
|
| Sep 18 |
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
|
| Sep 18 |
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
|
| Aug 15 |
Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript
|
| Aug 15 |
Vivos Therapeutics GAAP EPS of -$0.60, revenue of $4.1M
|
| Aug 14 |
Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
|
